Bolt Biotherapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Bolt Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $19.00K, a 35.71% increase year-over-year.
- Bolt Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $5.00K, a 82.76% decline year-over-year.
- Bolt Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- Bolt Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $14.00K, a 82.28% decline year-over-year.
- Bolt Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $19.00K, a 82.41% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $108.00K, a 56.28% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $247.00K, a 32.88% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $368.00K, a 42.50% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $19.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $19.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2025-06-30 | $14.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $108.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2024-06-30 | $79.00K 10-Q · filed 2025-08-14 | |
| 2023-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $247.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-06-30 | $141.00K 10-Q · filed 2024-08-13 | |
| 2022-12-31 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $368.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-06-30 | $224.00K 10-Q · filed 2023-08-07 | |
| 2021-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $640.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2021-06-30 | $420.00K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |